Condition
Cancer, Thyroid
Total Trials
4
Recruiting
2
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
P 2 (2)
Trial Status
Recruiting2
Enrolling By Invitation1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06458036Phase 2Recruiting
Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)
NCT05783323Phase 2Recruiting
Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer
NCT06583395Enrolling By Invitation
Quest to Analyze One Thousand Humans Meditating
NCT03307694CompletedPrimary
Thyroid Ultrasound Elasticity (TrUE) Imaging
Showing all 4 trials